Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. cut its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,312 shares of the medical equipment provider’s stock after selling 46 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Intuitive Surgical were worth $2,804,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Provence Wealth Management Group purchased a new stake in Intuitive Surgical during the fourth quarter worth about $276,000. Portside Wealth Group LLC lifted its holdings in Intuitive Surgical by 8.2% during the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock worth $275,000 after buying an additional 62 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in Intuitive Surgical by 58.0% in the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after buying an additional 3,054 shares during the period. Kades & Cheifetz LLC acquired a new position in shares of Intuitive Surgical in the fourth quarter worth $230,000. Finally, Blair William & Co. IL increased its position in shares of Intuitive Surgical by 3.1% during the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock worth $110,302,000 after acquiring an additional 11,400 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ ISRG traded up $3.71 during trading on Friday, reaching $381.36. The company’s stock had a trading volume of 1,028,858 shares, compared to its average volume of 1,492,254. The business’s fifty day moving average price is $385.40 and its 200-day moving average price is $349.30. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $403.76. The firm has a market cap of $135.27 billion, a price-to-earnings ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the previous year, the firm posted $1.00 EPS. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Robert W. Baird lowered their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Truist Financial lifted their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Piper Sandler lifted their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Finally, Mizuho increased their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $396.17.

Insider Transactions at Intuitive Surgical

In related news, EVP Robert Desantis sold 20,296 shares of Intuitive Surgical stock in a transaction on Friday, March 8th. The shares were sold at an average price of $393.80, for a total value of $7,992,564.80. Following the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,168,656.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, President David J. Rosa sold 80,710 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $389.28, for a total value of $31,418,788.80. Following the sale, the president now directly owns 163,399 shares in the company, valued at $63,607,962.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. Insiders sold 226,928 shares of company stock worth $87,833,828 over the last 90 days. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.